Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.
CONSHOHOCKEN, Pa., Feb. 28, 2025 /PRNewswire/ -- The GBS | CIDP Foundation International today released new survey data illustrating how people with Guillain-Barré Syndrome experience this life ...
In lieu of flowers, please consider a donation to the GBS/CIDP Foundation International or to Penn State St. Joseph Medical Center. Online condolences can be made at maestumpfuneralhome.com ...
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting Targeted for 1H 2025 Ahead of Planned Biologics License ...